刺猬 (Hh) 信号通路参与细胞事件的各个方面。Hh 信号通路的异常激活驱动了多种癌症的致癌转化,因此它是癌症治疗的一个有希望的目标。本着缔合和开环原理,我们设计合成了一系列具有苯基咪唑支架的Hh信号通路抑制剂,并在Gli-Luc报告基因检测中进行了生物学评估。化合物25被鉴定为具有纳摩尔 IC 50 的高效能,此外,它保留了对野生型和耐药性 Smo 过表达细胞的抑制作用。化合物25的分子模型研究 阐述了其与Smo受体的结合方式,为苯基咪唑类似物的进一步结构修饰提供了基础。
刺猬 (Hh) 信号通路参与细胞事件的各个方面。Hh 信号通路的异常激活驱动了多种癌症的致癌转化,因此它是癌症治疗的一个有希望的目标。本着缔合和开环原理,我们设计合成了一系列具有苯基咪唑支架的Hh信号通路抑制剂,并在Gli-Luc报告基因检测中进行了生物学评估。化合物25被鉴定为具有纳摩尔 IC 50 的高效能,此外,它保留了对野生型和耐药性 Smo 过表达细胞的抑制作用。化合物25的分子模型研究 阐述了其与Smo受体的结合方式,为苯基咪唑类似物的进一步结构修饰提供了基础。
The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).
Synthesis of 2-methoxybenzamide derivatives and evaluation of their hedgehog signaling pathway inhibition
作者:Chiyu Sun、Dajun Zhang、Tian Luan、Youbing Wang、Wenhu Zhang、Lin Lin、Meihua Jiang、Ziqian Hao、Ying Wang
DOI:10.1039/d1ra00732g
日期:——
Aberrant hedgehog (Hh) signaling is implicated in the development of a variety of cancers. Smoothened (Smo) protein is a bottleneck in the Hh signal transduction. The regulation of the Hh signaling pathway to target the Smo receptor is a practical approach for development of anticancer agents. We report herein the design and synthesis of a series of 2-methoxybenzamide derivatives as Hh signaling pathway
异常刺猬 (Hh) 信号传导与多种癌症的发展有关。平滑 (Smo) 蛋白是 Hh 信号转导的瓶颈。调节 Hh 信号通路以靶向 Smo 受体是开发抗癌药物的实用方法。我们在此报告了一系列 2-甲氧基苯甲酰胺衍生物作为 Hh 信号通路抑制剂的设计和合成。药理学数据表明,化合物21具有有效的 Hh 通路抑制作用,具有纳摩尔 IC 50值,并且它阻止了 Shh 诱导的 Smo 进入初级纤毛。此外,通过化合物21有效抑制了突变体 Smo 。体外的化合物21对耐药细胞系的抗增殖活性产生了令人鼓舞的结果。
[EN] N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF<br/>[FR] N-(3-HÉTÉROARYLARYL)-4-ARYLARYLCARBOXAMIDES ET ANALOGUES COMME INHIBITEURS DE LA VOIE HEDGEHOG ET LEUR UTILISATION
申请人:IMPACT THERAPEUTICS INC
公开号:WO2014012511A1
公开(公告)日:2014-01-23
Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.
N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof
申请人:IMPACT Therapeutics, Inc.
公开号:US20150191460A1
公开(公告)日:2015-07-09
Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D
1
-D
4
, Q
1
, Q
2
, R
5
are defined herein. Compounds having Formula (I) are hedgehog pathway inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of hedgehog activity, such as cancer.
A green and highly efficient synthesis of a naphthyridine derivative, a novel hedgehog pathway modulator, in high yield and purity from inexpensive starting materials is described. The key step involves an acid-promoted aryl amination reaction of aniline with naphthyridine halides.